Atopic Dermatitis Ad Epidemiology Forecast

DelveInsight's "Atopic dermatitis (AD) - Epidemiology Forecast- 2032" report delivers an in-depth understanding of the AD, historical and forecasted AD epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

AD Disease Understanding

Atopic dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word ‘dermatitis,’ ‘derm’ means ‘skin’ and ‘itis’ means ‘inflammation.’ Thus, dermatitis is a skin inflammation characterized by itchiness, redness and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances.

 

AD presents different symptoms depending on the age of the person. Itching is the hallmark of AD; more than 85% of people with the condition experience this distressing symptom every day. The exact cause of AD is unknown. The basic understanding of AD is that inflammation results from compromised skin barrier leading to drier skin that is more prone to water loss and the entry of irritants. Thus, AD is caused by a complex interaction of immune dysregulation, epidermal gene mutations, and environmental factors that disrupt the epidermis causing intensely pruritic skin lesions.

 

There is currently no reliable biomarker that can distinguish the disease from other entities. However, the most commonly used biomarker is elevated total and/or allergen-specific serum IgE. Occasionally, patients carrying an AD diagnosis may display atypical clinical features, chronic dermatoses, infectious processes, and primary immunodeficiency may mimic the presentation leading to the differential diagnosis. Noninfectious dermatoses include contact dermatitis, seborrheic dermatitis, and psoriasis.

 

At present, there is no specific test for AD, and no single symptom or feature can be used to identify the disease. Each patient has a unique combination of symptoms and rash appearance. Diagnosis of AD is based on the history and physical examination of the patient. In uncertain cases, a skin biopsy may be taken for a histopathological diagnosis of dermatitis.

AD Epidemiology

The AD epidemiology division provides insights about historical and current AD patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted AD epidemiology [segmented as total prevalent cases of AD, total diagnosed prevalent cases of AD, severity-specific distribution of AD in adults, severity-specific distribution of  AD in pediatric population, gender-specific prevalence of AD in adults, diagnosed prevalent cases of pruritus in AD in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise AD Epidemiology

  • Estimates show that the highest cases of AD in the 7MM were in the United States, followed by Japan, Germany, the United Kingdom, Italy, France, and Spain in the year 2021.
  • As per DelveInsight estimates, total prevalent population of AD in the seven major markets was 65,445,311 cases in 2021. The cases in the 7MM are expected to increase during the study period, i.e., 2019–2032.
  • As per DelveInsight estimates the total diagnosed prevalent population of AD cases were highest in the United States. The diagnosed prevalent cases were estimated to be 24,193,284 in 2021 in the US.
  • As per the analysis, in the US, mild AD accounted for the highest cases in 2021, followed by moderate to severe AD with 9,713,457 and 6,458,373, respectively, in adults.
  • In the EU5 countries, the prevalent population of AD was maximum in Germany with 6,002,742 cases, followed by the UK with 5,393,687 cases in 2021. While, the least number of cases were in Spain, with 3,304,045 cases in 2021.
  • Among the gender-specific prevalent contribution, females are affected more by AD than males. In 2021, there were 6,090,942 cases of AD in males and 10,095,456 cases in females in the US.
  • The diagnosed prevalence of chronic pruritus in AD cases in the US was 13,758,438 in 2021.
  • As per DelveInsight estimates, Japan accounted for 6,938,196 diagnosed prevalent cases of AD in 2021.

Scope of the Report

  • The report covers the descriptive overview of AD, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the AD epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for AD are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of AD market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global AD market

Report Highlights

  • In the coming years, AD market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence AD R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
  • Major players are involved in developing therapies for AD. Launch of emerging therapies will significantly impact the AD market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for AD
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

AD Report Insights

  • Patient Population
  • Therapeutic Approaches
  • AD Pipeline Analysis
  • AD Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

AD Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • AD Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

AD Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Epidemiology Insights:

  • What is the disease risk, burden and regional/ethnic differences of the AD?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical AD patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of AD in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to AD?
  • Out of all AD countries, which country would have the highest prevalent population of AD during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the AD market
  • To understand the future market competition in the AD market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for AD in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for AD market
  • To understand the future market competition in the AD market

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. SWOT Analysis

6. Atopic Dermatitis Epidemiology Overview at a Glance

6.1. Patient Share (%) Distribution by Class of Therapies of Atopic Dermatitis in 2022

6.2. Patient Share (%) Distribution by Class of Therapies of Atopic Dermatitis in 2032

7. Disease Background and Overview

7.1. Signs and Symptoms

7.2. Causes and Triggers

7.3. Clinical presentation

7.4. Pathophysiology

7.5. Skin hypersensitivity – abnormalities of the horny cell layer

7.5.1. Mechanisms involved in inflammation

7.5.2. Pruritus

7.6. Biomarkers

7.6.1. Serum IgE levels

7.6.2. Peripheral eosinophil count

7.6.3. Serum lactate dehydrogenase level

7.6.4. Serum thymus and activation regulated chemokine level

7.7. Characteristics of eruption

7.7.1. Infancy (younger than 2 years)

7.7.2. Childhood/school-age (2–12 years old)

7.7.3. Adolescence/adulthood (13 years and older)

7.8. Differential diagnosis

7.9. Prevention and Management

7.10. Diagnosis

7.11. Diagnostic criteria for eczema

8. Stress-Relieving Therapies

9. Atopic Dermatitis Clinical Guideline: American Academy of Dermatology Association (2014)

10. Atopic eczema in under 12s: Diagnosis and management by NICE (updated 2020)

11. Consensus-based European guidelines for the treatment of atopic eczema (atopic dermatitis) in adults and children (2018)

12. Epidemiology and Patient Population

12.1. Key Findings

12.2. Epidemiology Methodology

12.3. 7MM Prevalent Population of Atopic dermatitis

12.4. 7MM Diagnosed Prevalent Population of Atopic dermatitis

12.5. Assumption and Rationale

12.5.1. United States

12.5.2. EU5

12.5.3. Japan

12.6. The United States

12.6.1. Diagnosed Prevalent Population of Atopic Dermatitis in the United States

12.6.2. Severity-specific distribution of Atopic Dermatitis in Adults in the United States

12.6.3. Severity-specific distribution of Atopic Dermatitis in Pediatric Population in the United States

12.6.4. Gender-specific Prevalence of Atopic Dermatitis in adults in the United States

12.6.5. Chronic Pruritus Prevalence in Atopic Dermatitis in Adults in the United States

12.7. EU5

12.7.1. Diagnosed Prevalent Population of Atopic Dermatitis in EU5

12.7.2. Severity-specific distribution of Atopic Dermatitis in Adults in EU5

12.7.3. Severity-specific distribution of Atopic Dermatitis in Pediatric Population in EU5

12.7.4. Gender-specific Cases of Atopic Dermatitis (AD) in EU5

12.7.5. Chronic Pruritus Prevalence in Atopic Dermatitis in Adults in EU5

12..8. Japan

12.8.1. Diagnosed Prevalent Population of Atopic Dermatitis in Japan

12.8.2. Severity-specific distribution of Atopic Dermatitis in Adults in Japan

12.8.3. Severity-specific distribution of Atopic Dermatitis in Pediatric Population in Japan

12.8.4. Gender-specific Prevalence of Atopic Dermatitis in adults in Japan

12.8.5. Chronic Pruritus Prevalence in Atopic Dermatitis in adults in Japan

14. Organizations contributing towards AD

15. Appendix

15.1. Bibliography

15.2. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

List of Tables

Table 1: Summary of Atopic Dermatitis Epidemiology (2019–2032)

Table 2: Key Events

Table 3: Characteristic features of Atopic Dermatitis by age

Table 4: Diagnostic features for eczema

Table 5: Hanifin and Rajka Criteria for Atopic Dermatitis

Table 6: UK working party diagnostic criteria for eczema

Table 7: Topical Corticosteroids Ranked by Potency (from Most Potent to Least Potent)

Table 8: Features to be considered in the diagnosis of patients with AD

Table 9: Dosing and monitoring guidelines for the use of selected systemic agents

Table 10: Total Prevalent Population of Atopic dermatitis in the 7MM (2019–2032)

Table 11: Diagnosed Prevalent Population of Atopic dermatitis in the 7MM (2019–2032)

Table 12: Diagnosed Prevalent Population of AD in the US (2019–2032)

Table 13: Severity-specific distribution of Atopic Dermatitis in Adults in the US (2019–2032)

Table 14: Severity-specific distribution of Atopic Dermatitis in Pediatric Population in the US (2019–2032)

Table 15: Gender-specific Prevalence of Atopic Dermatitis in adults in the US (2019–2032)

Table 16: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in the US (2019–2032)

Table 17: Total Prevalent Population of AD in EU5 (2019–2032)

Table 18: Total Diagnosed Prevalent Population of AD in EU5 (2019–2032)

Table 19: Severity-specific Cases of AD in EU5 (2019–2032)

Table 20: Severity-specific Cases of AD in Pediatric Population EU5 (2019–2032)

Table 21: Gender-specific Cases of AD in EU5 (2019–2032)

Table 22: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in EU5 (2019–2032)

Table 23: Prevalent Population of Atopic Dermatitis in Japan (2019–2032)

Table 24: Diagnosed Prevalent Population of AD in Japan (2019–2032)

Table 25: Severity-specific distribution of Atopic Dermatitis in Adults in Japan (2019–2032)

Table 26: Severity-specific distribution of Atopic Dermatitis in Pediatric Population in Japan (2019–2032)

Table 27: Gender-specific Prevalence of Atopic Dermatitis in adults in Japan (2019–2032)

Table 28: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in Japan (2019–2032)

Table 29: Organizations contributing toward AD

List of Figures

Figure 1: Total Prevalent Population of Atopic dermatitis in the 7MM (2019–2032)

Figure 2: Diagnosed Prevalent Population of Atopic dermatitis in the 7MM (2019–2032)

Figure 3: Diagnosed Prevalent Population of Atopic Dermatitis in the US (2019–2032)

Figure 4: Severity-specific distribution of Atopic Dermatitis in Adults in the US (2019–2032)

Figure 5: Severity-specific distribution of AD in Pediatric Population in the US (2019–2032)

Figure 6: Gender-specific Prevalence of Atopic Dermatitis in adults in the US (2019–2032)

Figure 7: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in the US (2019–2032)

Figure 8: Total Prevalent Population of AD in EU5 (2019–2032)

Figure 9: Total Diagnosed Prevalent Population of AD in EU5 (2019–2032)

Figure 10: Severity-specific Cases of AD in Adults in EU5 (2019–2032)

Figure 11: Severity-specific Cases of AD in Pediatric Population in EU5 (2019–2032)

Figure 12: Gender-specific Cases of AD in EU5 (2019–2032)

Figure 13: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in EU5 (2019–2032)

Figure 14: Prevalent Population of Atopic Dermatitis in Japan (2019–2032)

Figure 15: Diagnosed Prevalent Population of Atopic Dermatitis in Japan (2019–2032)

Figure 16: Severity-specific distribution of Atopic Dermatitis in Adults in Japan (2019–2032)

Figure 17: Severity-specific distribution of AD in Pediatric Population in Japan (2019–2032)

Figure 18: Gender-specific Prevalence of Atopic Dermatitis in adults in Japan (2019–2032)

Figure 19: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in Japan (2019–2032)

Forward to Friend

Need A Quote